All the Active Ingredient Drugs
Bevacizumab 25 mg/ml. VIALS: 1 x 100 mg/4 ml; 1 x 400 mg/16ml
Metastatic carcinoma of the colon or rectum (mCRC)
5 mg/kg or 10 mg/kg once every 2 weeks or 7.5 mg/kg or 15 mg/kg once every 3 weeks. until progression of dis. or unacceptable tox.
Metastatic breast cancer (mBC)
10 mg/kg once every 2 weeks or 15 mg/kg once every 3 weeks until progression of dis. or unacceptable tox.
Non-small cell lung cancer (NSCLC)
First-line tmt. of non-squamous NSCLC in combin. with platinum-based chemother.:
in addition to platinum-based chemother. for up to 6 cycles of tmt. followed by this drug as a sgle. agent until dis. progress. 7.5 mg/kg or 15 mg/kg once every 3 weeks. Clinical benefit in NSCLC pts. has been demonstrated with both 7.5 mg/kg and 15 mg/kg doses. until progress. of dis. or unacceptable tox.
First-line tmt. of non-squamous NSCLC with EGFR activating mutations in combin. with erlotinib:
EGFR mutation testing should be performed prior to init. of tmt with the combin. of this drug and erlotinib. It is important that a well-validated and robust methodology is chosen to avoid false neg. or false posit. determination.
15 mg/kg once every 3 weeks until dis. progress.
Advanced and/or metastatic renal cell cancer (mRCC)
10 mg/kg once every 2 weeks until progress. of the dis. or unacceptable tox.
Malignant Glioma (WHO Grade IV) - Glioblastoma
10 mg/kg once every 2 weeks or 15 mg/kg once every 3 weeks. until progress. of dis. or unacceptable tox.
Epithelial ovarian, fallopian tube and primary peritoneal cancer
Front-line tmt.:
in addition to carboplatin and paclitaxel for up to 6 cycles of tmt. followed by cont. use of this drug as sgle. agent until dis. progress or for a max. of 15 months or until unacceptable tox., whichever occurs earlier. Dose of this prod. is 15 mg/kg once every 3 weeks.
Tmt. of platinum-sensitive recurrent dis.
in combin. with carboplatin and gemcitabine for 6 cycles and up to 10 cycles followed by cont. use of this drug as sgle. agent until dis. progress. Dose is 15 mg/kg once every 3 weeks.
Tmt. of platinum-resistant recurrent dis.
In combin. with one of the following – paclitaxel, topotecan (given weekly) or pegylated liposomal doxorubicin. The dose of this drug is 10 mg/kg once every 2 weeks. When admin. in comb. with topotecan (on days 1-5, every 3 weeks), the dose of this drug is 15 mg/kg g once every 3 weeks. until dis. progress. or unacceptable tox.
Cervical Cancer
in comb. with one of the following chemother. regimens: paclitaxel and cisplatin or paclitaxel and topotecan. The dose of this drug is 15 mg/kg once every 3 weeks. until progress. of dis. or until unacceptable tox.
In comb. with fluoropyrimidine-based chemother -tmt. of pts. with metastatic carcinoma of the colon or rectum.
In comb. with paclitaxel - first-line tmt. of adlt. pts. with metastatic breast cancer.
In addition to platinum-based chemother- first-line tmt. of pts. with unresectable adv. metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
In comb. with erlotinib -first-line tmt of adlt. pts. with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.
In combin. with interferon alfa-2a - first line tmt. of pts. with adv. and/or metastatic renal cell cancer.
As a single agent, - tmt. of glioblastoma in patients with progress. dis. following prior ther.
In combin. with carboplatin and paclitaxel - front-line tmt. of advanced ([FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at high risk for recurrence (residual disease after debulking).
In comb. with carboplatin and gemcitabine, - tmt. of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior ther. with bevacizumab or other VEGF inhibit. or VEGF receptor-targeted agents.
In combin. with paclitaxel, topotecan, or pegylated liposomal doxorubicin – ttmt. of adult pts. with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemother. regimens and who have not received prior ther. with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.
In combinat. with paclitaxel and cisplatin or, paclitaxel and topotecan, - tmt. of pts. with persistent, recurrent, or metastatic carcinoma of the cervix
C/I: Hypersens
Hypersens. to Chinese Hamster Ovary (CHO) cell prod. or other recomb. human or humanised antibodies. Pregn.
Monoclonal Antibody, VEGF Inhibitor. Bevacizumab 25 mg/ml. VIALS: 1 x 100 mg/4 ml; 1 x 400
mg/16ml.
Dosage adjust. individ. for each pt.
accord to the med. cond. accord. to
prescr. info.
Tmt. metastat. Carcinoma of the colon or
rectum, to be used in combinat. With
fluoropyrimidine-based chemother.
Firstline tmt. metastat. Breast cancer, in
comb. with Paclitaxel. tmt.
unresect.,advanced, metastat./recurrent
NSCLC other than predom. squamous cell
histology, in add. to platinum-based
chemother. tmt. advanc./metastat. Renal
cell cancer, in comb. with interferon alfa-
2a. Firstline tmt. advanc./metastat. Renal
cell cancer, in comb. with interferon alfa-
2a. As single agent tmt. glioblastom. In
pts. with progress. dis. foll. prior ther.
Front-line tmt. in comb. with paclitaxel.
and carboplatin advanc. (FIGO III B, III
C,IV) epithelial ovar., fallop. tube, or
primary peritoneal canc. in pts at high risk
for recurrence (resid. dis. aft.debulk.). in
comb. with carboplatin and gemcitabine
tmt of adult pts. with first recur.of
platinum-sensit. epithelial ovar., fallopian
tube or prim. peritoneal cancer who have
not received prior therapy with
Bevacizumab or other VEGF inhibit. or
VEGF receptor–targeted agents.
C/I: Hypersens. active substance/
excips./ chinese hamster ovary/ other recombinant human or humanized
antibodies., pregn.
Monoclonal Antibody, VEGF Inhibitor. Bevacizumab 25 mg / 1 ml. Concentr. for sol. for IV vials:1 X 4 ml/16ml
Dosage to be adj. indiv. as per med. condit. and combinat. regimen accord. to prescrib. info.
In combin. with fluoropyrimidine-based chemother. for metast. carcin. of the colon or rectum.- In addit. to platinum - based chemoth. for first - line tmt. of unresectable adv. metast. or recurr. non- small cell lung cancer other than predom. squam. cell histol. –In combin. with interferon alfa-2a for first line of adv. and /or metast. renal cell cancer. In combin. with paclitaxel for first-line tmt. of metast. breast cancer.- As a sgle. agent, for glioblastoma in pts. with progress. dis. following prior ther.- In combin. with carboplatin and paclitaxel, for front-line tmt. of adv.(FIGO stages III B, III C and IV) epithelial ovarian, fallopian tube, or prim. peritoneal cancer at high risk for recurr.- In combin. with carboplatin and gemcitabine, for first recurr. of platinum-sensit. epithelial ovarian, fallopian tube or prim. peritoneal cancer pts. who have not received prior ther. with bevacizumab or other VEGF inhibit. or VEGF receptor-targeted agents.- In combin. with topotecan, or pegylated liposomal doxorubicin for platinum-resistant recurr. epithelial ovarian, fallopian tube, or prim. peritoneal cancer pts. who received no more than 2 prior chemother. regimens and who have not receved prior ther. with bevacizumab or other VEGF inhib. or VEGF recept.–targeted agents –In combin. with paclitaxel and cisplatin or paclitaxel and topotecan for persistent, recurr., or metast. carcin. of the cervix.- In combin. with erlotinib, for first-line tmt. of unresectable adv., metast. or recurr. non-squam. non-small cell lung cancer with Epid. Growth Factor Recept.(EGFR) activat. mutat.
C/I: hypersens, incl. to Chin. Hamster Ovary (CHO) cell prod. or other recomb. human or humanized antibodies. Pregn.
Monoclonal Antibody. Bevacizumab 25 mg/ml. VIAL (Concent. for sol. for infus.):1×4 (100 mg),16 ml (400mg).
Dosage must be ajust. indivd. accord. to indicat. and pt. med. condit.
Tmt. of adult pts. with Metast.carcinoma of the colon or rectum: in comb.with fluoropyrimidine-based chemother.
1ST -line tmt. of adult pts. with metastat. breast cancer: in comb. with paclitaxel. For further informat., as to human epiderm. growth factor receptor 2 (HER2) status see lit.
1ST -line tmt. of adult pts. with unresectable advance., metastat. or recur. non-small cell lung cancer other than predominant. squamous cell histology in addition to platinum-based chemother.
1st -line tmt. of adult pts. with unresect. advanced, metastat. or recur. non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activat. mutations in comb. with erlotinib.
1ST -line tmt. of adult pts. with advance. and/or metastat. renal cell cancer: in comb. with interferon alfa-2a.
Tmt. of glioblastoma in pts. with progress. dis. follow. prior ther. as a single agent.
Front-line tmt. of advanced (FIGO stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer in pts. who are at high risk for recurrence (residual dis. after debulking): in comb. with carboplatin & paclitaxel. Tmt. of adult pts. with first recurrence of platinum-sensit. epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior ther. with bevacizumab or other VEGF inhib. or VEGF receptor-targeted agents: in comb. with carboplatin and gemcitabine, is indicat. for MVASI in comb. with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the tmt. of adult pts. with platinum-resist. recur. epithelial ovarian, fallopian tube, or prim. peritoneal cancer who received no more than two prior chemother. regimens and who have not received prior ther. with bevacizumab or other VEGF inhib. or VEGF receptor-targeted agents.
Tmt. of adult pts. with persist., recur.,or metastat. carcinoma of the cervix, in pts. who cannot receive platinum ther. in comb.with paclitaxel &cisplatin or, paclitaxel & topotecan.
C/I: Hypersens.
Hypersens. to Chinese Hamster Ovary (CHO) cell products or other recomb.human or humanized antibod.
Preg.
